Navigation Links
Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Date:12/6/2011

PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System in patients with type 1 and type 2 diabetes.  Data from the study confirm that Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.  Echo also announced that it plans to conduct a study in critical care patients in the near term.

"This study represents another major step in our Symphony development program.  We have now shown that Symphony represents a novel approach for the tracking and trending of glucose in patients with diabetes and holds great potential to make a meaningful impact in the management of this growing disease.  Importantly, a recent, major U.S. study demonstrated that real-time, continuous glucose monitoring gives people with type 2 diabetes, in addition to those with type 1 diabetes, improved blood glucose control," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are extremely pleased with the outcome of the study and look forward to the continued success of our Symphony tCGM program, including the upcoming trial in critical care patients."

Study Results

Using over 2,600 Symphony tCGM glucose readings from the twenty (20) study subjects paired with reference blood glucose measurements, CG-EGA showed that 94.4% of the readings were clinically accurate and 2.5% were benign errors with a combined A+B of 96.9%. The MARD for the study was 12.6%.  Values for blood glucose measurements ranged from 38 to 399 mg/dL. There were no adverse events reported from the Prelude skin pe
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Vermillion, Inc. (Nasdaq:   VRML), ... announced today that investors including Oracle Investment Management, ... and several Vermillion directors have agreed to purchase ... common stock and warrants to purchase unregistered shares ... Under the terms of the ...
(Date:12/22/2014)... PA & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across ... Society for Clinical Data Management (SCDM) to provide ... and certification programs —providing access to the more ... partnership extends SCDM members with 10% off when registering ...
(Date:12/22/2014)... MISSION VIEJO, Calif. , Dec. 22, 2014 /PRNewswire/ ... announce that CoPatient, an online medical bill review and ... newest offering in the FREE WellCard Savings discount health ... a medical bill that was more than they expected ... help members reduce health care costs, WellCard Savings is ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Md., Oct. 23 United,Therapeutics Corporation (Nasdaq: ... 2008 third quarter financial results before market open ... host a half-hour teleconference on Thursday,October 30, 2008, ... by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... Soliris(R) in U.S. and Europe, Reported Net Sales ... Quarter Shipments, Company Revises Revenue Guidance Upward and ... 2008, Pipeline Progress in Hematology, Oncology, Transplant, Neurology, ... (eculizumab) net product sales of $76.5 million in Q3,2008 ...
... TheBrain,s dynamic interface enhances Web community and presence by visualizing ... , ... Marina del Rey, CA (PRWEB) ... software, announces that MedTechIQ has published several "Bioinfomediary Brains", on ...
Cached Biology Technology:Alexion Reports Third Quarter 2008 Results 2Alexion Reports Third Quarter 2008 Results 3Alexion Reports Third Quarter 2008 Results 4Alexion Reports Third Quarter 2008 Results 5Alexion Reports Third Quarter 2008 Results 6Alexion Reports Third Quarter 2008 Results 7Alexion Reports Third Quarter 2008 Results 8Alexion Reports Third Quarter 2008 Results 9Alexion Reports Third Quarter 2008 Results 10Alexion Reports Third Quarter 2008 Results 11Alexion Reports Third Quarter 2008 Results 12Alexion Reports Third Quarter 2008 Results 13Alexion Reports Third Quarter 2008 Results 14MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 2MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 3MedTechIQ Selects TheBrain to Visualize Expansive Biointellingence Database and Connect the Dots Between Life Sciences, Medicine and Venture Capital 4
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... ice formation occurred in the Arctic earlier than previously ... week in Nature . "The results are also ... in the Arctic before it did in Antarctica, which ... Richard Pearce of the University of Southampton,s School of ...
... 14, 2009 -- The stress of rising natural gas prices ... homes. For some this means moving towards modern alternative ... traditional method for a solution to these rising costs. ... been reevaluated as a potentially viable option for home heating. ...
... Va.The Journal of Vascular and Interventional Radiology ,s quality ... years, and the increase in its impact factor to 2.217 ... radiology, nuclear medicine and medical imaging journals, according to results ... continues to see a rise in its impact, the Society ...
Cached Biology News:Early initiation of Arctic sea-ice formation 2Early initiation of Arctic sea-ice formation 3Wood stoves -- a viable home heat source? 2Journal of Vascular and Interventional Radiology increases impact, international reach 2Journal of Vascular and Interventional Radiology increases impact, international reach 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
15(S)-HETE-d8 is used as an internal standard for the quantification of 15(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: